Method for determining trace nitrite in pharmaceutic adjuvant

By employing UPLC-MS/MS technology and DAN derivatization reaction, the problem of rapid and accurate quantification of trace nitrites in pharmaceutical excipients has been solved, achieving detection with high sensitivity and accuracy. This method is applicable to the detection of nitrites in pharmaceutical excipients, active pharmaceutical ingredients, and finished pharmaceutical products.

CN121741086APending Publication Date: 2026-03-27LINGCHUAN PHARM TECH (SHANDONG) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511613133.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-11-06
Publication Date
2026-03-27

AI Technical Summary

Technical Problem

Existing technologies are insufficient for the rapid and accurate determination of trace amounts of nitrite in pharmaceutical excipients, especially in complex matrices where there is significant interference, and cannot meet the quality control requirements for nitrosamine impurities.

Method used

Ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used in conjunction with the derivatization reaction of 2,3-diaminonaphthalene (DAN) to convert nitrite into 1-H-naphtho[2,3-d][1,2,3]triazole (NAT), and quantification was performed using multiple reaction monitoring (MRM) mode. This optimized chromatographic and mass spectrometric conditions reduced interference and improved sensitivity and accuracy.

Benefits of technology

It enables rapid and accurate quantification of trace nitrites in drug samples, with a quantification limit at the pg/ml level, significantly improving the sensitivity and accuracy of detection, and is suitable for quality control of complex drug matrices.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121741086A_ABST
    Figure CN121741086A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of analytical chemistry detection, in particular to a method for determining trace nitrite in pharmaceutic adjuvants.The method comprises the steps that an acetonitrile solution, a potassium hydroxide solution, a phosphate buffer solution, a sulfuric acid solution, a 2, 3-diaminonaphthalene solution and a reference substance working solution are provided; the method comprises the following steps: preparing a standard curve solution and a test sample solution, and carrying out ultra-high performance liquid chromatography-tandem mass spectrometry analysis detection: respectively carrying out sample injection detection on the test sample solution and the prepared standard curve solutions with different concentrations under preset chromatographic conditions and mass spectrometry conditions, recording detection results of the standard curve solutions with different concentrations to make a standard curve, and calculating the content of nitrite in the test solution by adopting a standard addition method according to the standard curve and the detection result of the test solution. The method disclosed by the invention can be used for rapidly determining trace nitrite in a drug sample, and can be used for determining the trace nitrite in pharmaceutical adjuvants and detecting the nitrite in drugs.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application relates to the field of analytical chemistry detection technology, and particularly relates to a method for determining trace nitrite in pharmaceutical excipients by using Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS / MS) technology. BACKGROUND

[0002] A number of studies have shown that N-nitrosamines are strong genotoxic substances, some of which are classified as possible or potential human carcinogens. Therefore, the European Medicines Agency (EMA) has forced the marketing authorization holder to conduct a risk assessment on all pharmaceutical products to assess the risk of N-nitrosamine impurities. N-nitrosamines are formed when nitrite reacts with secondary or tertiary amines, especially under acidic conditions. Studies have found that trace amounts of nitrite in pharmaceutical excipients are the main source of nitrosating agents in pharmaceutical preparations. Unlike secondary and tertiary amines, nitrite is a universal precursor of all N-nitrosamines, so establishing a sensitive and accurate analytical method to determine trace amounts of nitrite in pharmaceutical excipients is an effective means to control the generation of genotoxic impurities of N-nitrosamines in pharmaceutical preparations.

[0003] In most excipients, the content of nitrite can reach the level of one part per million (ppm). Unfortunately, the specific source of nitrite in excipients, raw materials and intermediates has not been systematically studied. The source of these trace levels of nitrite may include process water, process steps requiring acid titration, bleaching process, and may also come from the oxidation of air in the drying process. For the determination of nitrite, ion chromatography, spectrophotometry, fluorescence method, and derivatization method are usually used; among them, spectrophotometry and ion chromatography are more commonly used in the determination of nitrite in pharmaceuticals and food. There are documents reporting the use of spectrophotometry to determine the content of nitrite in pharmaceutical excipients, but the limit of quantification is 0.2 μg / ml, which cannot meet the requirements of N-nitrosamine impurity determination; ion chromatography can quickly, sensitively and accurately determine nitrite, but the method of ion chromatography reported in the literature for the determination of nitrite in pharmaceutical excipients is difficult to accurately measure due to the complexity of different excipient matrices and more interference; derivatization methods include High Performance Liquid Chromatography (HPLC) and HPLC-MS methods, which have a limit of quantification of ng / ml level. However, for drugs with complex matrix or extremely low N-nitrosamine impurity limit, it is difficult to meet the quality control requirements of trace nitrite in their excipients. SUMMARY

[0004] The present application aims at overcoming the above-mentioned defects of the prior art, and provides a method for determining trace nitrite in pharmaceutical excipients by using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS) detection technology, which can quickly determine trace nitrite in pharmaceutical samples, and the quantitative limit concentration can reach the pg / ml level, has less interference, high accuracy, and higher sensitivity than HPLC and HPLC-MS, and can be used for determining trace nitrite in pharmaceutical excipients and detecting nitrite in drugs.

[0005] To achieve the above-mentioned object, the embodiments of the present application provide the following technical solutions: The present application provides a method for determining trace nitrite in pharmaceutical excipients, which adopts ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS) technology and comprises the following steps: Step (1), providing determination solvents and reagents, including acetonitrile solution, potassium hydroxide solution, phosphate buffer, sulfuric acid solution, 2,3-diaminonaphthalene solution and control product working solution; Step (2), preparing a standard curve solution: a plurality of control product working solutions are weighed and placed in a volumetric flask, acetonitrile solution, 2,3-diaminonaphthalene solution and sulfuric acid solution are added according to the proportion, the reaction mixture of the control product working solution is ultrasonically treated at room temperature, the phosphate buffer is added to terminate the reaction, the acetonitrile solution is used to dilute to the target volume, the supernatant is taken after centrifugal treatment, and the acetonitrile solution is used to dilute, so as to obtain the standard curve solution; Step (3), preparing a test product solution: the test product is weighed and placed in a volumetric flask, acetonitrile solution, 2,3-diaminonaphthalene solution and sulfuric acid solution are added according to the proportion, the reaction mixture of the test product is ultrasonically treated at room temperature, the phosphate buffer is added to terminate the reaction, the acetonitrile solution is used to dilute to the target volume, the supernatant is taken after centrifugal treatment, and the acetonitrile solution is used to dilute, so as to obtain the test product solution; Step (4), using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS) analysis and detection: the test product solution obtained in step (3) and the standard curve solutions with different concentrations prepared in step (2) are respectively injected for detection under preset chromatographic conditions and mass spectrometric conditions, the detection results of the standard curve solutions with different concentrations are recorded to make a standard curve, and the content of nitrite in the test product solution is calculated by using the standard addition method according to the detection results of the standard curve and the test product solution.

[0006] As a further scheme of the present application, the determination solvents and reagents are provided as follows: Solvent: 30% acetonitrile solution; 45% (w / w, weight ratio / weight concentration) potassium hydroxide solution: 45 g of potassium hydroxide is weighed, dissolved in 55 ml of ultrapure water, and shaken uniformly; 1 mol / L phosphate buffer: potassium phosphate dibasic 8.71 g was weighed, added to 40 ml ultrapure water, dissolved, added 10 ml potassium hydroxide solution, mixed well; 25% (v / v, volume ratio / volume concentration) sulfuric acid solution: 10 ml sulfuric acid was measured and slowly added to 30 ml ultrapure water; 0.1 mol / L 2,3-diaminonaphthalene solution (DAN, derivatization reagent): 2,3-diaminonaphthalene 158 mg was weighed, added to 10 ml acetonitrile, dissolved, and shaken well; Control sample working solution: nitrite (nitrite 20 mg) was dissolved and diluted with a solvent to prepare a solution containing about 25 ng of nitrite per 1 ml.

[0007] As a further scheme of the present application, when preparing the standard curve solution, 0.05 ml, 0.1 ml, 0.2 ml, 0.5 ml, 1.0 ml, and 2 ml of the control sample working solution were precisely measured, respectively, and placed in a 100 ml brown volumetric flask, 10 ml of the solvent (30% acetonitrile solution) was added, 100 μl of the DAN reagent (2,3-diaminonaphthalene solution) and 0.5 ml of the 25% sulfuric acid solution were added, the reaction mixture of the control sample working solution was ultrasonically treated at room temperature for 10 minutes, 2 ml of the 1 mol / L phosphate buffer was added to terminate the reaction, the volume was adjusted to 100 ml with the solvent (30% acetonitrile solution), centrifugation (10000 rpm) was performed for 5 minutes, and the supernatant was diluted 5 times with the solvent to obtain the standard curve solution.

[0008] As a further scheme of the present application, when preparing the test sample solution, 250 mg of the test sample was weighed and placed in a 100 ml brown volumetric flask, 10 ml of the solvent (30% acetonitrile solution) was added, 100 μl of the DAN reagent (2,3-diaminonaphthalene solution) and 0.5 ml of the 25% sulfuric acid solution were added, the reaction mixture of the test sample solution was ultrasonically treated at room temperature for 10 minutes, 2 ml of the 1 mol / L phosphate buffer was added to terminate the reaction, the volume was adjusted to 100 ml with the solvent, centrifugation (10000 rpm) was performed for 5 minutes, and the supernatant was diluted 5 times with the solvent to obtain the test sample solution.

[0009] As a further scheme of the present application, the test sample is selected from one of mannitol, carboxymethyl starch sodium, magnesium stearate, povidone, lactose, sodium citrate, microcrystalline cellulose, hydroxypropyl methyl cellulose, calcium hydrogen phosphate, low-substituted hydroxypropyl cellulose, cross-linked povidone, carboxymethyl cellulose calcium, and cross-linked sodium carboxymethyl cellulose.

[0010] As a further scheme of the present application, the chromatographic conditions of ultra-high performance liquid chromatography-tandem mass spectrometry include: Chromatographic column: Waters C18, 2.1 x 100 mm, 1.7 μm; Column temperature: 40℃; Flow rate: 0.2 mL / min; Injection volume: 5 μL; Mobile phase: mobile phase A is 0.1% formic acid solution, mobile phase B is methanol; A gradient elution program is used.

[0011] As a further scheme of the present application, the mass spectrometry conditions of the ultra-high performance liquid chromatography-tandem mass spectrometry include: Ion source: electrospray ionization (ESI); Scan mode: positive ion mode; Detection mode: multiple reaction monitoring (MRM); Parameters: capillary voltage is 3500V, atomizer pressure is 40psi, dryer temperature is 400℃, dryer flow rate is 9L / min, sheath gas temperature is 300℃, sheath gas flow rate is 5mL / min; The quantitative ion pair of 1-H-naphtho[2,3-d][1,2,3]triazole (NAT) is used for detection.

[0012] As a further scheme of the present application, the quantitative ion pair includes parent ions and daughter ions with specific m / z values, and the collision energy and Fragmentor voltage are set according to the standard optimization.

[0013] As a further scheme of the present application, the method further includes data analysis and result verification steps, and the qualitative confirmation and quantitative calculation are performed through the mass spectrum, wherein the detection limit is 0.5 pg / mL, and the quantitative limit is 2.5 pg / mL.

[0014] Compared with the prior art, the technical scheme provided by the present application has the following beneficial effects: The method for determining trace nitrite in pharmaceutical excipients provided by the present application can quickly determine the trace nitrite in a drug sample, and the quantitative limit concentration can reach the pg / ml level. Compared with the spectrophotometry and ion chromatography, the present application is much higher than the traditional spectrophotometry (usually μg / mL level) and ion chromatography (usually ng / mL level), has less interference, high accuracy, and higher sensitivity than the HPLC method and the HPLC-MS method. By using the determination method of the present application, the content of trace nitrite in pharmaceutical excipients can be accurately and quantitatively determined, the generation of nitrosamine genotoxic impurities in drug preparations can be effectively controlled, and the present application is especially suitable for drug quality control with extremely low requirements for nitrosamine impurities.

[0015] The method of the application also converts nitrite into 1-H-naphtho[2,3-d][1,2,3]triazole (NAT) through a 2,3-diaminonaphthalene (DAN) derivatization reaction in the method, significantly improves the specificity of detection, and reduces the interference of complex matrixes (such as pharmaceutical excipients); combined with the multiple reaction monitoring (MRM) mode of UPLC-MS / MS, the quantification is performed through the selection of specific ion pairs, further eliminates the interference of impurities, and improves the detection accuracy; the ultra-high performance liquid chromatography (UPLC) technology is adopted, the particle size of the chromatographic column is small (1.7 μm), the column efficiency is high, and the analysis time is short, so that the detection efficiency is significantly improved; the derivatization reaction only needs 10 minutes under ultrasonic treatment at room temperature, which is faster than the traditional heating derivatization method (usually more than 30 minutes); all reactions are carried out in brown volumetric flasks, so as to avoid the degradation of derivatization products caused by photolysis, and ensure the stability of the results; through the optimization of the termination reaction conditions (the addition of phosphate buffer) and the centrifugal dilution step, the consistency and reproducibility of sample processing are ensured; the method of the application is not only suitable for the detection of nitrite in pharmaceutical excipients, but also can be extended to complex pharmaceutical matrixes such as raw pharmaceuticals and finished preparations, and through the adjustment of derivatization reaction and chromatography-mass spectrometry conditions, the samples of different matrix types can be adapted, and the universality is strong.

[0016] These aspects or other aspects of the application will be more apparent in the following description of the embodiments. It should be understood that the above general description and the following detailed description are only exemplary and explanatory, and cannot limit the application. BRIEF DESCRIPTION OF DRAWINGS

[0017] In order to more clearly illustrate the technical solutions in the embodiments of the application or the related art, the following will briefly introduce the drawings needed to be used in the exemplary embodiments or the related art description. The drawings are used to provide further understanding of the application, and constitute a part of the specification. The drawings are used together with the embodiments of the application to explain the application, and do not constitute a limitation on the application. In the drawings: Figure 1 The limit of detection solution spectrum diagram in the determination method of trace nitrite in a pharmaceutical excipient according to an embodiment of the application.

[0018] Figure 2 The limit of quantification solution spectrum diagram in the determination method of trace nitrite in a pharmaceutical excipient according to an embodiment of the application. DETAILED DESCRIPTION

[0019] In order to make the purpose, technical scheme and advantages of the application more clear, the following will further illustrate the application with embodiments. It should be understood that the specific embodiments described here are only used to explain the application, and cannot limit the application.

[0020] The technical solutions in the exemplary embodiments of the present application will be clearly and completely described below. Obviously, the described exemplary embodiments are only part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative work fall within the protection scope of the present application.

[0021] Specifically, the embodiments of the present application are further described.

[0022] Embodiment 1

[0023] The embodiments of the present application provide a method for determining trace nitrite in a pharmaceutical excipient. The method is used for determining the content of trace nitrite in mannitol, a pharmaceutical excipient. The determination method comprises the following operations: 1. Experimental materials and reagents Test sample: mannitol; Water: ultrapure water-18.2 megaohms; Formic acid: mass spectrometry grade; Methanol: mass spectrometry grade; Acetonitrile: mass spectrometry grade; Mobile phase A (0.1% formic acid solution): measure 1 ml of formic acid in a solvent bottle, add 1 L of ultrapure water, and shake well; Mobile phase B: methanol; Diluent (30% acetonitrile solution): measure 300 ml of acetonitrile and 700 ml of ultrapure water, and mix well; Potassium hydroxide solution: 45% (w / w), weigh 45 g of potassium hydroxide and dissolve in 55 mL of ultrapure water; Phosphate buffer (1 mol / L): weigh 8.71 g of potassium hydrogen phosphate, add 40 mL of ultrapure water to dissolve, add 10 mL of potassium hydroxide solution, and mix well; Sulfuric acid solution: 25% (v / v), measure 10 mL of sulfuric acid and slowly add to 30 mL of ultrapure water; Derivative reagent: 0.1 mol / L 2,3-diaminonaphthalene (DAN) solution, weigh 158 mg of DAN and dissolve in 10 mL of acetonitrile; Control working solution: weigh an appropriate amount of sodium nitrite (equivalent to 20 mg of nitrite), dissolve with 30% acetonitrile solution and dilute step by step to contain 25 ng of nitrite per 1 mL; Triple quadrupole liquid chromatograph-mass spectrometer: equipped with an electrospray ion source (ESI); Ultrasonic cleaner; Electronic balance.

[0024] 2. Determination steps 2.1 Preparation of standard curve solution: Accurately pipette 0.05 mL, 0.1 mL, 0.2 mL, 0.5 mL, 1.0 mL and 2.0 mL of the working solution of the reference substance (25 ng / mL) into 100 mL brown volumetric flasks, respectively, and add 10 mL of 30% acetonitrile solution, 100 μL of DAN reagent and 0.5 mL of 25% sulfuric acid solution. Ultrasonically treat the reaction mixture at room temperature for 10 minutes, add 2 mL of 1 mol / L phosphate buffer to terminate the reaction, dilute to the calibration mark with 30% acetonitrile solution, centrifuge (10000 rpm) for 5 minutes, dilute the supernatant 5 times with 30% acetonitrile solution, and obtain a series of standard curve solutions (concentration range: 2.5-100 pg / mL).

[0025] 2.2 Preparation of the test sample solution: Weigh about 250 mg of the test sample of mannitol into a 100 mL brown volumetric flask, add 10 mL of 30% acetonitrile solution, 100 μL of DAN reagent and 0.5 mL of 25% sulfuric acid solution. Ultrasonically treat the reaction mixture at room temperature for 10 minutes, add 2 mL of 1 mol / L phosphate buffer to terminate the reaction, dilute to the calibration mark with 30% acetonitrile solution, centrifuge (10000 rpm) for 5 minutes, dilute the supernatant 5 times with 30% acetonitrile solution, and obtain the test sample solution.

[0026] 2.3 UPLC-MS / MS analysis conditions: 2.3.1 Chromatographic conditions: Chromatographic column: Waters C18 (2.1 x 100 mm, 1.7 μm); Column temperature: 40°C; Flow rate: 0.2 mL / min; Injection volume: 5 μL; Mobile phase: A (0.1% formic acid solution), B (methanol); Gradient program: 0-2 min (5% B), 2-5 min (5%-95% B), 5-7 min (95% B), 7-7.1 min (95%-5% B), 7.1-10 min (5% B).

[0027] 2.3.2 Mass spectrometric conditions: Ion source: electrospray ion source (ESI); Scanning mode: positive ion mode; Detection mode: multiple reaction monitoring (MRM); Parameters: capillary voltage 3500 V, atomizer pressure 40 psi, desiccator temperature 400°C, desiccator flow rate 9 L / min, sheath gas temperature 300°C, sheath gas flow rate 5 mL / min; NAT quantitative ion pair: m / z 169.1→141.1 (collision energy 15 eV, Fragmentor voltage 110 V).

[0028] 2.4 Determination and calculation: The series of standard curve solutions and test sample solutions were respectively injected and analyzed, and the peak area of the NAT was recorded. The standard curve (linear range: 2.5-100 pg / mL, r²>0.999) was drawn with the concentration of the standard curve solution as the abscissa and the peak area as the ordinate. The nitrite content in the test sample was calculated by the standard curve method.

[0029] 2.5 Experimental results: The standard curve: the linear equation was y=18524x+86.7, r²=0.9996, indicating that the linearity was good in the range of 2.5-100 pg / mL; Limit of detection and limit of quantification: the limit of detection was 0.5 pg / mL, and the limit of quantification was 2.5 pg / mL; Precision: the test sample solution was determined for 6 times in succession, and the RSD was 2.1% (n=6); Spiked recovery rate: the nitrite standard (2.5 pg / mL, 25 pg / mL, 50 pg / mL) was added to the test sample at low, medium and high concentration levels, and the recovery rates were 98.5%, 101.2% and 99.8% (RSD<3%) respectively; Sample determination result: the nitrite content in the mannitol was 0.38 ng / g.

[0030] The embodiment successfully verifies the applicability of the UPLC-MS / MS method provided by the application in determining the trace nitrite in the pharmaceutical excipient mannitol. The method has high sensitivity (limit of quantification 2.5 pg / mL), high accuracy (recovery rate 98.5%-101.2%) and good precision (RSD<3%), and completely meets the quality control requirements of trace nitrite in pharmaceutical excipients in complex matrix.

[0031] Example 2

[0032] The embodiment of the application provides a determination method of trace nitrite in pharmaceutical excipients, which is used for determining the content of trace nitrite in the pharmaceutical excipient magnesium stearate. The determination method comprises the following operations: 1. Experimental materials and reagents Test sample: magnesium stearate; Water: ultrapure water-18.2 megaohm; Formic acid: mass spectrometry grade; Methanol: mass spectrometry grade; Acetonitrile: mass spectrometry grade; Mobile phase A (0.1% formic acid solution): take 1 mL formic acid in a solvent bottle, add 1 L ultrapure water, shake well; Mobile phase B: methanol; Diluent (30% acetonitrile solution): take 300 mL acetonitrile and 700 mL ultrapure water, mix well; Potassium hydroxide solution: 45% (w / w), weigh 45 g of potassium hydroxide and dissolve in 55 mL of ultrapure water; Phosphate buffer (1 mol / L): weigh 8.71 g of potassium phosphate dibasic, add 40 mL of ultrapure water to dissolve, add 10 mL of potassium hydroxide solution, mix well; Sulfuric acid solution: 25% (v / v), take 10 mL of sulfuric acid and slowly add to 30 mL of ultrapure water; Derivative reagent: 0.1 mol / L 2,3-diaminonaphthalene (DAN) solution, weigh 158 mg of DAN and dissolve in 10 mL of acetonitrile; Control working solution: weigh an appropriate amount of sodium nitrite (equivalent to 20 mg of nitrite), dissolve with 30% acetonitrile solution and dilute step by step to contain 25 ng of nitrite per 1 mL; Triple quadrupole liquid chromatograph-mass spectrometer: equipped with an electrospray ion source (ESI); Ultrasonic cleaner; Electronic balance.

[0033] 2. Determination steps 2.1 Preparation of standard curve solution: Precisely take 0.05 mL, 0.1 mL, 0.2 mL, 0.5 mL, 1.0 mL, and 2.0 mL of the control working solution (25 ng / mL) into 100 mL brown volumetric flasks, respectively, and add 10 mL of 30% acetonitrile solution, 100 μL of DAN reagent, and 0.5 mL of 25% sulfuric acid solution. Ultrasonically treat the reaction mixture at room temperature for 10 minutes, add 2 mL of 1 mol / L phosphate buffer to terminate the reaction, dilute to the mark with 30% acetonitrile solution, centrifuge (10000 rpm) for 5 minutes, and dilute the supernatant 5 times with 30% acetonitrile solution to obtain a series of standard curve solutions (concentration range: 2.5-100 pg / mL).

[0034] 2.2 Preparation of test sample solution: About 250 mg of the sample of magnesium stearate was taken into a 100 mL brown volumetric flask, 10 mL of 30% acetonitrile solution, 100 μL of D AN reagent and 0.5 mL of 25% sulfuric acid solution were added. The reaction mixture was ultrasonically treated at room temperature for 10 minutes, 2 mL of 1 mol / L phosphate buffer was added to terminate the reaction, diluted to the calibration mark with 30% acetonitrile solution, centrifuged (10000 rpm) for 5 minutes, and the supernatant was diluted 5 times with 30% acetonitrile solution to obtain the sample solution.

[0035] 2.3 UPLC-MS / MS analysis conditions: 2.3.1 Chromatographic conditions: Chromatographic column: Waters C18 (2.1 x 100 mm, 1.7 μm); Column temperature: 40 °C; Flow rate: 0.2 mL / min; Injection volume: 5 μL; Mobile phase: A (0.1% formic acid solution), B (methanol); Gradient program, wherein the mobile phase gradient program is shown in Table 1: Table 1 Gradient elution program

[0036] 2.3.2 Mass spectrometry conditions: Ion source: electrospray ion source (ESI); Scan mode: positive ion mode; Detection mode: multiple reaction monitoring (MRM); Parameters: capillary voltage 3500 V, nebulizer pressure 40 psi, dry er temperature 400 °C, dry er flow rate 9 L / min, sheath gas temperature 300 °C, sheath gas flow rate 5 mL / min; NAT quantitative ion pair: m / z 170.1→115.1 (collision energy 25 V, Fragmentor voltage 90 V), wherein the quantitative ion pair, collision energy and Fragmentor voltage are shown in Table 2.

[0037] Table 2 NAT quantitative ion pair, collision energy and Fragmentor voltage

[0038] 2.4 Determination and calculation: The series of standard curve solutions and sample solutions were respectively injected and analyzed, and the peak area of NAT was recorded. The standard curve (linear range: 2.5-100 pg / mL, r²>0.999) was plotted with the concentration of the standard curve solution as the abscissa and the peak area as the ordinate. The content of nitrite in the sample was calculated by the standard curve method, see Figure 1and Figure 2 as shown.

[0039] The embodiment successfully verifies the applicability of the UPLC-MS / MS method provided by the application in determining trace nitrite in the pharmaceutical excipient magnesium stearate. The method has high sensitivity (quantification limit 2.5 pg / mL), high accuracy (recovery rate 98.5%~101.2%), and good precision (RSD <3%), and fully meets the quality control requirements of trace nitrite in pharmaceutical excipients in complex matrix.

[0040] It should be noted that: in this embodiment, magnesium stearate and mannitol are taken as examples to show the whole process from sample treatment, purification to instrument analysis and result calculation. In actual operation, the amount of acetonitrile, shaking time and other conditions can be fine-tuned within the range of the parameters according to the properties of the specific test product.

[0041] The above only describes the preferred embodiments of the application and should not be used to limit the application. Any modification, equivalent replacement and improvement made within the spirit and principle of the application should be included in the protection scope of the application.

Claims

1. A method for determining trace amounts of nitrite in pharmaceutical excipients, characterized in that, Includes the following steps: Step 1) Provide the assay solvents and reagents, including: acetonitrile solution, potassium hydroxide solution, phosphate buffer, sulfuric acid solution, 2,3-diaminonaphthalene solution and reference working solution; Step 2) Preparation of standard curve solution: Weigh multiple sets of reference working solutions and place them in volumetric flasks. Add acetonitrile solution, 2,3-diaminonaphthalene solution and sulfuric acid solution according to the ratio. After sonicating the reaction mixture of reference working solutions at room temperature, add phosphate buffer to terminate the reaction. Make up to the target volume with acetonitrile solution. After centrifugation, take the supernatant and dilute it with acetonitrile solution to obtain the standard curve solution. Step 3) Preparation of test solution: Weigh the test sample and place it in a volumetric flask. Add acetonitrile solution, 2,3-diaminonaphthalene solution and sulfuric acid solution according to the ratio. After sonicating the reaction mixture of the test sample at room temperature, add phosphate buffer to terminate the reaction. Make up to the target volume with acetonitrile solution. After centrifugation, take the supernatant and dilute it with acetonitrile solution to obtain the test solution. Step 4) Analyze using ultra-high performance liquid chromatography-tandem mass spectrometry: Inject the test solution obtained in step 3) and the standard curve solutions of different concentrations prepared in step 2) into the test solution under preset chromatographic and mass spectrometric conditions. Record the detection results of the standard curve solutions of different concentrations to create a standard curve. Based on the standard curve and the detection results of the test solution, calculate the nitrite content in the test solution using the standard addition method.

2. The method for determining trace nitrite in pharmaceutical excipients as described in claim 1, characterized in that, The following solvents and reagents are provided for the assay: Solvent: 30% acetonitrile solution; 45% potassium hydroxide solution: Weigh 45g of potassium hydroxide, add 55ml of ultrapure water to dissolve, and shake well; 1 mol / L phosphate buffer: Weigh 8.71 g of dipotassium hydrogen phosphate, dissolve it in 40 ml of ultrapure water, add 10 ml of potassium hydroxide solution, and mix well; 25% sulfuric acid solution: Measure 10ml of sulfuric acid and slowly add it to 30ml of ultrapure water; 0.1 mol / L 2,3-diaminonaphthalene solution: Weigh 158 mg of 2,3-diaminonaphthalene, add 10 ml of acetonitrile to dissolve, and shake well; Reference working solution: Weigh nitrite, of which 20 mg of nitrite ions are dissolved and diluted with solvent to prepare a solution containing approximately 25 ng of nitrite ions per 1 ml.

3. The method for determining trace nitrite in pharmaceutical excipients as described in claim 2, characterized in that, To prepare the standard curve solution, accurately measure 0.05 ml, 0.1 ml, 0.2 ml, 0.5 ml, 1.0 ml, and 2 ml of the reference working solution, respectively, and place them in a 100 ml brown volumetric flask. Add 10 ml of 30% acetonitrile solution, 100 μl of 2,3-diaminonaphthalene solution, and 0.5 ml of 25% sulfuric acid solution. Sonicate the reaction mixture of the reference working solution at room temperature for 10 minutes. Add 2 ml of 1 mol / L phosphate buffer to terminate the reaction. Make up the volume to 100 ml with 30% acetonitrile solution, centrifuge for 5 minutes at 10,000 rpm, and dilute the supernatant 5 times with solvent to obtain the standard curve solution.

4. The method for determining trace nitrite in pharmaceutical excipients as described in claim 2, characterized in that, To prepare the test solution, weigh 250 mg of the test sample and place it in a 100 ml brown volumetric flask. Add 10 ml of 30% acetonitrile solution, 100 μl of 2,3-diaminonaphthalene solution, and 0.5 ml of 25% sulfuric acid solution. Sonicate the reaction mixture of the test solution at room temperature for 10 minutes. Add 2 ml of 1 mol / L phosphate buffer to terminate the reaction. Make up the volume to 100 ml with solvent and centrifuge for 5 minutes at 10,000 rpm. Take the supernatant and dilute it 5 times with solvent to obtain the test solution.

5. The method for determining trace nitrite in pharmaceutical excipients as described in claim 4, characterized in that, The test sample is selected from one of mannitol, sodium carboxymethyl starch, magnesium stearate, povidone, lactose, sodium citrate, microcrystalline cellulose, hydroxypropyl methylcellulose, calcium hydrogen phosphate, low-substituted hydroxypropyl cellulose, crospovidone, calcium carboxymethyl cellulose, and sodium crospovidone carboxymethyl cellulose.

6. The method for determining trace nitrite in pharmaceutical excipients as described in claim 1, characterized in that, The chromatographic conditions for ultra-high performance liquid chromatography-tandem mass spectrometry include: Column: Waters C18, 2.1 × 100 mm, 1.7 μm; Column temperature: 40℃; Flow rate: 0.2 mL / min; Injection volume: 5 μL; Mobile phase: Mobile phase A is 0.1% formic acid solution, and mobile phase B is methanol; A gradient elution procedure was used.

7. The method for determining trace nitrite in pharmaceutical excipients as described in claim 6, characterized in that, The mass spectrometry conditions for ultra-high performance liquid chromatography-tandem mass spectrometry include: Ion source: Electrospray ionization source; Scanning mode: positive ion mode; Detection method: Multiple reaction monitoring; Parameters: capillary voltage 3500V, nebulizer pressure 40psi, dryer temperature 400℃, dryer flow rate 9L / min, sheath gas temperature 300℃, sheath gas flow rate 5mL / min; Detection was performed using NAT's quantitative ion pairing.

8. The method for determining trace nitrite in pharmaceutical excipients as described in claim 7, characterized in that, The quantitative ion pair includes a parent ion and a daughter ion with specific m / z values, and the collision energy and fragmentor voltage are optimized according to standards.

9. The method for determining trace nitrite in pharmaceutical excipients as described in claim 1, characterized in that, The method also includes data analysis and result verification steps, with qualitative confirmation and quantitative calculation performed by mass spectrometry, wherein the detection limit is 0.5 pg / mL and the quantitation limit is 2.5 pg / mL.